After completing the comprehensive assessment of all potentially relevant off-target edits in the targeted genome, SeQure Dx uses its ScopeSeQ assay to determine the biologic impact of the predicted off-target editing. Our confirmation assay utilizes next generation sequencing in either edited cells or tissue from targeted organs to assess the in vivo outcomes of gene editing.
Workflow
